The concept advanced by Berridge and colleagues that intracellular Ca 2+ -stores can be mobilized in an agonist-dependent and messenger (IP 3 )-mediated manner has put Ca 2+ -mobilization at the center stage of signal transduction mechanisms. During the late 1980s, we showed that Ca 2+ -stores can be mobilized by two other messengers unrelated to inositol trisphosphate (IP 3 ) and identified them as cyclic ADP-ribose (cADPR), a novel cyclic nucleotide from NAD, and nicotinic acid adenine dinucleotide phosphate (NAADP), a linear metabolite of NADP. Their messenger functions have now been documented in a wide range of systems spanning three biological kingdoms. Accumulated evidence indicates that the target of cADPR is the ryanodine receptor in the sarco/endoplasmic reticulum, while that of NAADP is the two pore channel in endolysosomes.
In 1983, Berridge and colleagues published a study showing that agonists, such as carbachol, can activate Ca 2+ release from non-mitochondrial Ca 2+ stores and the effect is mediated by a Ca 2+ messenger, inositol 1,4,5-trisphosphate (IP 3 ) [1] . The targeted Ca 2+ stores were later identified as the endoplasmic reticulum (ER), which has since been shown to be the major intracellular Ca 2+ stores. This seminal study ushered in the current field of Ca 2+ signaling as we know it and has made the field center stage. IP 3 is derived from a phospholipid, phosphatidyl inositol 4,5-bisphosphate, present on the cytoplasmic side of the plasma membrane. Agonist binding to its specific receptor leads to activation of phospholipase C and the hydrolysis of the phospholipid, releasing the head group that is IP 3 . The structure of IP 3 is shown in Figure 1 . It has three phosphates on the inositol ring. Both the number of phosphates and the position of the phosphates are critical to the binding of IP 3 to its receptor in the ER. The space-filling model of IP 3 shown in Figure 1 is based on the crystal coordinates of IP 3 bound to its receptor [2] .
With the IP 3 -pathway elucidated, two obvious questions follow; namely, whether there are other Ca 2+ signaling- pathways present in cells and whether there are Ca 2+ stores other than the ER. The answers to both questions are affirmative and are the focus of this article. As will be described below, the other Ca 2+ signaling pathways are mediated by two novel Ca 2+ mobilizing messengers, cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP). Neither their structures nor the substrates they derive from have any similarity with those of IP 3 , however. Both these new messengers are nucleotides. Cyclic ADP-ribose is derived from NAD, while NAADP is from NADP. The Ca 2+ stores they target are also different; cADPR acts on the ER, similar to IP 3 , but NAADP targets the lysosome-like acidic stores. Nevertheless, both these nucleotide messengers are synthesized by the same multi-functional signaling enzyme, CD38. They are thus fraternal twin messengers for Ca 2+ signaling.
Discovery of cADPR and NAADP
The discovery of the nucleotide messengers was made in the late 1980s [3, 4] , a few years after the elucidation of the IP 3 -pathway. The strategy devised was to isolate the endoplasmic Ca 2+ stores and use them as an in vitro assay for Ca 2+ release activators [5] . The cell selected was sea urchin egg because it has an abundant and elaborate ER system, and had been a well studied system for the release of internal Ca 2+ on fertilization [6] . The endoplasmic preparations made from the eggs are remarkably stable and responded well to IP 3 as expected. What was unanticipated was that both NAD and NADP were equally effective in releasing Ca 2+ from the preparations [3] . Both NAD and NADP are coenzymes of oxidative reactions in cells and neither had ever been suspected to be involved in Ca 2+ signaling. The Ca 2+ release induced by NAD showed a characteristic delay distinctly different from the immediate release induced by IP 3 , as can be seen from Figure 2 . This was shown to be due to enzymatic conversion of NAD to an active metabolite that was later identified as cADPR, a novel cyclic nucleotide hitherto unknown [4, 7] . Its structure is shown in Figure  1 . During the enzymatic conversion, the nicotinamide group of NAD is cleaved and the N1 of the adenine is linked back to the terminal ribose, forming a head to tail circle. The space-filling model in the figure is rendered using the crystal coordinates of cADPR [7] . Based on the structure, a total chemical synthesis of cADPR, a tour de force, has been achieved [8] and a large number of analogs have since been produced (reviewed in [9] ). That cADPR is in fact a natural metabolite endogenously present in tissues was first shown in rats, using sea urchin egg microsomes as a bioassay for cADPR (Figure 2) [10].
Unlike NAD, NADP induced Ca 2+ release without a delay as shown in Figure 2 . The release was not, however, due to NADP, but a minute contaminant in the commercial preparations of NADP that was later identified as [56] [57] [58] . Similar activation of the TRPM2 channel is seen in primary cells, such as neutrophils [55] and pancreatic β-cells [56] .
TRPM2 is a member of the M-family of transient receptor potential channels (reviewed in [59] ). These channels are widely expressed in many tissues and are best recognized for their contributions to sensory transduction, including response to temperature. The first identified activating ligand for TRPM2 is ADP-ribose (ADPR), a hydrolysis product of cADPR [60] [61] [62] [63] . Indeed, cADPR also can activate the TRPM2 channel and the action of both molecules is synergistic, such that in the presence of low concentrations of ADPR, the EC 50 value of cADPR for activating the channel is greatly reduced [57, 58] .
Studies in insulinoma cells and pancreatic islets show that the physiological consequence of the cADPR-dependent Ca 2+ influx via TRPM2 is stimulation of insulin secretion [56, 64] . Evidence also points to TRPM2 being a temperature sensor in the cells, whose activity is modulated by cADPR [56] . In neuronal cells, cADPR activates TRPM2 in a temperature dependent manner similar to that observed in the islet cells and is responsible for signaling oxytocin release [65, 66] . In human bone marrow mesenchymal stem cells, modulation of TRPM2 by cADPR increases the frequency of Ca 2+ oscillation, resulting in enhanced cell proliferation [67, 68] .
NAADP targets the two-pore channels in lysosomes
That NAADP targets a novel Ca 2+ -release mechanism distinct from all known mechanisms was clear from the vary start. This is because the NAADP-mechanism is insensitive to all known inhibitors of the IP 3 -, cADPR-and RyR-mechanisms [3, 11] . The only way to block the mechanism is to self-desensitize it using high concentrations of NAADP [69, 70] . That NAADP targets a specific and novel receptor was also clear, because any structural modifications on either the 2′-phosphate, the N6-amino group, or the carboxyl group on the nicotinic acid moiety, render it inactive [71] . Even the Ca 2+ stores it targets are separate from the ER. This was first shown by fractionation of the sea urchin egg homogenates. The NAADP-responsive organelles were found at the bottom of the Percoll density gradients, well separated from the cADPR-sensitive ER that were on the top of the gradient [72] . More convincingly, in situ stratification of the organelles in live sea urchin eggs using centrifugation combined with Ca 2+ -imaging, showed that the NAADP-sensitive stores were located at a pole of the stratified eggs that was separate and opposite to that of the cADPR-and IP 3 -sensitive stores [73] . The distinctive organelles were subsequently identified as the reserve granules, a lysosome-related organelle in the eggs [74] . The finding was confirmed in mammalian cells as well [31, 75] (reviewed in [76] ).
Searches were thus directed at ion channels localized in the lysosomes as possible candidate targets for NAADP. The two-pore channels (TPC 1-3) are members of a superfamily of voltage-gated ion channels and are localized in the lysosomes. In plant, TPC1 is found to mediate Ca 2+ release from vacuoles [77] . Transfection of TPC into HEK293 cells resulted in its expression in the lysosomes. Specific NAADP binding to lysosomes increased and the cells became responsive to NAADP, indicating TPC is the target of NAADP [78] . A similar conclusion was reached by two other independent groups [79, 80] .
Further support came from direct measurements of the NAADP-dependent currents through the TPC, using isolated lysosomes that were enlarged by vacuolin treatment and patched using a glass chip-based technique. The permeability of the TPC was found to be at least 1000-fold more selective for Ca 2+ than for K + and was activatable by NAADP only when the intralysosomal pH was acidic [81] . The amino acid Glu643 in the putative pore region was identified as critical for the Ca 2+ selectivity and its mutation to alanine reduced the permeability ratio of Ca 2+ to K + by more than 120 times [81] . Similar results were obtained using immunopurified TPCs that were reconstituted into lipid bilayers. The single channel Ca 2+ conductance of about 15 pS was measured, which is 4 or 8 times less than that of the IP 3 -recpetor or RyR, respectively. The purified TPC also showed enriched specific binding to NAADP [82, 83] . Collectively, these results leave little doubt that the TPCs are the endogenous targets of NAADP (reviewed in [84] ).
Enzymatic synthesis of cADPR by CD38
As described above, it was the presence of the enzymatic activity in sea urchin egg homogenates converting NAD to cADPR that had led to its discovery ( Figure 2 ). This enzymatic activity was not limited to sea urchin egg homogenates but was wide spread among mammalian tissue extracts as well [85] . The first purified enzyme that catalyzes the cyclization of NAD to cADPR was a soluble protein of 30 kD from Aplysia [86, 87] . The enzyme was previously thought to be a common NADase that hydrolyzes NAD to ADPR [86] , as cADPR was a hitherto unknown molecule. The enzymatic product was eventually shown to be, in fact, cADPR and not ADPR. The Aplysia enzyme was thus named ADP-ribosyl cyclase (Cyclase) to distinguish it from common NADases [87] . A very convenient assay was later developed for measuring the cyclization of NAD by using nicotinamide guanine dinucleotide (NGD), an analog of NAD, as substrate. The cADPR synthesizing enzymes, like the Cyclase, cyclize NGD to cyclic GDP-ribose, a fluorescent product, while conventional NADase hydrolyzes it to non-fluorescent GDP-ribose [88] .
Based on the amino acid sequence of the Cyclase, CD38, an antigen expressed in lymphocytes, was found to be homologous [89] . CD38 was later shown to be able to, indeed, cyclize NAD to cADPR [90] [91] [92] [93] . Unlike the Cyclase, CD38 catalyzes not only cADPR production but also the hydrolysis of cADPR to ADPR. In fact, when NAD is used as a substrate, the vast majority of the product is ADPR and not cADPR [90] [91] [92] [93] . This again had raised confusion about whether CD38 was a Cyclase or a NADase. The issue was fortunately resolved by the newly available NGDassay [88, 94, 95] . The lack of a specific and sensitive assay for cADPR that had led to all the confusion has finally been overcome by the development of a fluorimetric assay for cADPR with nanomolar sensitivity and based on a coupled enzyme technique [96] .
That CD38 is indeed responsible for synthesizing cADPR in tissues was shown by using CD38 knockout mice, whose endogenous cADPR in many tissues was greatly reduced [55] . The mice also manifest multiple defects relating to Ca 2+ signaling, including that of insulin secretion [97] , hormonal signaling in pancreatic acinar cells [98] , migration of dendritic cell precursors [99] , bone resorption [100] , airway responsiveness [101] , α-adrenoceptor signaling in aorta [102] , cardiac hypertrophy [103] , susceptibility to bacterial infection [55] , as well as social behavior in mice through modulation of oxytocin secretion [66] . In humans, the deletion of the CD38 gene may well be lethal since no CD38-negative individual has yet been identified in a large screen [104] . These results thus document the importance of the CD38/cADPR-pathway in regulating diverse physiological functions.
Enzymatic synthesis of NAADP by CD38
As described above, NAADP was discovered as a contaminant. That it is indeed naturally occurring was first shown in sea urchin sperm [105] and eggs [106] , and later in cells from other species as well, including mammals [107] . That NAADP is derived from NADP, instead of NAD, and targets the lysosomal Ca 2+ -stores instead of the ER, would suggest that it should be synthesized by an enzyme different from CD38. Surprisingly, this is not the case. CD38, in fact, is multi-functional and can catalyze yet a base-exchange reaction, exchanging the nicotinamide group in NADP with nicotinic acid [108] . The product is NAADP. This reaction occurs only in acidic pH, while the cyclization and hydrolysis of NAD(P) occur optimally at physiological pH. This remarkable property of CD38 has now been elucidated by using X-ray crystallography, as will be described below.
That CD38 is responsible for the endogenous synthesis of NAADP was shown using knockout mice, whose hepatic stellate cells exhibited altered angiotensin-signaling that is attributable to their inability to elevate the cellular levels of NAADP in response to angiotensin [109] . Similar results were found in lymphokine-activated killer cells. Cells from the knockout mice no longer could elevate NAADP levels in response to IL8 [110] . Likewise, wild type pancreatic acinar cells responded to physiological concentrations of CCK with elevation of intracellular NAADP and Ca 2+ , but both were blocked in the acinar cells from the knockout mice [111] .
Structure and catalytic mechanism of CD38
CD38 is thus a highly unusual enzyme that can use either NAD or NADP (with nicotinic acid) as substrates and convert it to cADPR or NAADP, respectively. How this can be accomplished by CD38 has now been elucidated to atomic resolution using X-ray crystallography and site-directed mutagenesis. Human CD38 is a membrane protein consisting of a short amino tail of 21 residues, a transmembrane segment of 23 hydrophobic residues and a large carboxyl domain (C-domain) of 256 residues [112] . There are also four glycosylation sites in the C-domain. These features make CD38 a difficult candidate for crystallography.
The effort had thus directed first toward its homolog, the Aplysia Cyclase, which is a soluble protein of 258 residues and without glycosylation. The crystal structure shows that it is a bean-shaped molecule with a central cleft. The amino portion consists mainly of helices, while all the β-structures are in the carboxyl portion [113] . Confirming the crosslinking studies in solution [114] , the Cyclase is also crystallized as a homo-dimer. The ten cysteines that are conserved with CD38 are all paired as disulfides. The active site was then identified by co-crystallization with nicotinamide [115] , a co-substrate for the base-exchange reaction. Residues at the site were systematically mutated to identify the catalytic residue as Glu179.
The crystal structure of the C-domain of CD38 reveals a high degree of structural homology with the Aplysia Cyclase [116] . The removal of the amino tail and the transmembrane segment, together with the mutation of the glycosylation sites, makes the domain crystallizable and produce structures with resolution as high as 1.5 Å [117, 118] . Glu226, which is equivalent to Glu179 in the Aplysia Cyclase, is identified as the catalytic residue as well [119] . Two other residues, Glu146 and Thr221, are shown to be the determinants that regulate the cyclization and hydrolysis reactions catalyzed by CD38. Thus, mutating Glu146 to alanine and Thr221 to phenylalanine converts CD38 to a Cyclase that produces mainly cADPR, instead of ADPR, from NAD. In fact, the catalytic properties of human CD38 and the Aplysia Cyclase can be inter-converted by mutating the equivalent residues respectively [120, 121] .
Glu146 in CD38, together with Asp155, also controls the base-exchange reaction, particularly its acidic pH dependency described above [122] . The negative charges of these residues electrostatically repel the similarly charged nicotinic acid at physiological pH and prevent its entry into the active site. Mutating the residues to uncharged amino acids eliminated the acidic dependency of the base-exchange reaction [122] . All the equivalent residues in the Cyclase also function similarly, showing the high degree of structural and functional conservation between human CD38 and the Aplysia Cyclase, even though the two species had diverged for hundreds of millions of years.
The entry of the substrate into the active site of CD38, the formation of the enzyme intermediates and the substrate cyclization process have all been captured by crystallography. Mutating the catalytic residue inactivates CD38 and allows its substrate complexes to be visualized by crystallography [117, 123] . NAD enters the active site pocket of CD38 with the nicotinamide end first. The catalytic Glu226 then forms hydrogen bonding with the hydroxyl groups of the terminal ribose, leading to the cleavage of the glycosidic bond and the release of the nicotinamide. An intermediate is formed. Both covalent [124] and non-covalent [123, 124] intermediates of CD38 have been observed, depending on the substrate. With arabinosyl-2′-fluoro-deoxy-nicotinamide adenine dinucleotide (ara-2′F-NAD) as substrate, an analog of NAD, Glu226 forms a covalent linkage with the anomeric carbon (C1R) of the terminal ribose [125] , as shown in Figures 3 and 4 . This anchors one end of the substrate to the active site and allows the folding of the adenine end during the cyclization to be observed.
Dynamic states of the cyclization of NAD have been captured in a single crystal of either CD38 or the Aplysia Cyclase [120, 125] . CD38 generally crystallizes with two molecules in each asymmetric crystal unit. However, when the covalent intermediate is formed with ara-2′F-NAD, CD38 crystallizes in the orthorhombic form, in the P2 1 2 1 2 1 space group, with six molecules in the crystal unit, as shown in Figure 3 [125] . Each molecule has a covalent intermediate at the active site and all of them have different conformations that can be grouped into two classes. The N1-intermediates have the N1 of the adenine pointing toward C1R of the terminal ribose, the cyclization site (left side in Figure 3 ), while the N7-intermediates have the N7 of the adenine pointing toward C1R instead. The CD38 molecules in the crystal unit that have the N1-intermediates are all adjacent and are colored with different shades of blue in Figure 3 , while those have the N7-intermediates are colored with shades of yellow. When the N1-molecules are aligned and all the N1-intermediates superimposed, it can be seen that their conformations represent states of folding of the adenine toward the site of cyclization ( Figure 4A ). In the closest approach, the distance between N1 and C1R is 3.2 Å, close enough for cyclization to occur. In the N7-conformation ( Figure 4B ), the distance becomes 9.6 Å (Figure 3) , too far for linkage and thus representing a nonproductive state. Similar observation has previously been made in the Aplysia Cyclase [120] . The conformation of the covalent intermediate in each of the two molecules in the crystal unit corresponds, respectively, to the N1-and N7-conformation, seen in CD38. The two conformations are actually equivalent because they can be mapped to each other by single-bond rotations [120] . Using NMR, it has been shown that the conformational features of the multiple molecules or 'conformers' in the crystal asymmetric unit correspond to those observed in solution for the ensemble of NMR conformers [126] . They are thus not artifactual, due to crystal packing, but may actually represent the true dynamic states of the cyclization of NAD by CD38 and the Cyclase.
Membrane topology and regulation of CD38
Elucidation of how the endogenous synthesis of cADPR and NAADP is regulated represents the next frontier of the field. The first indication obtained in sea urchin eggs is that the cADPR-production is stimulated by a cGMP-dependent process, most likely through phosphorylation of the enzyme [127, 128] . It has been proposed that cADPR and NAADP production may be differentially regulated by receptor-coupled second messengers, cGMP and cAMP, respectively [129] . However, cGMP-independent cADPR synthesis had also been found in the eggs [130] . In mammalian cells, both cGMP- [110, [131] [132] [133] and cAMP-dependent [134] [135] [136] [137] cADPR-synthesis have been reported. Likewise, in lymphokine-activated killer cells, NAADP synthesis is stimulated by both cAMP and cGMP [110] .
In granulocytes, treatments with 8Br-cAMP, a cellpermeant analog of cAMP, can increase serine phosphorylation of CD38 [135] . What is not known is which part of CD38 is phosphorylated, whether it is the catalytic C-domain or the amino tail. Intuitively, one would expect the phosphorylation site should be in the catalytic domain and may even be close to the active site, such that the enzymatic activity can be effectively modulated. This would necessitate the catalytic domain of CD38 to be facing the cytosol, in other words, a type-III membrane protein. This is, however, contrary to the general belief that CD38 is a type-II membrane protein, at least in the lymphocytes, with its C-domain on the outside [112] .
The type-II membrane topology also raises other problems of functionality, namely, substrate access and product targeting. Both NAD and the Ca 2+ stores that the products, cADPR and NAADP, target are located in the cytosol. This "topological paradox" has been addressed [138, 139] . It is shown that NAD can leak out of the cell via connexin hemi-channels [140, 141] and made available to the type-II CD38, while the product, cADPR, produced is transported back into the cell by nucleoside transporters present in the plasma membrane [142, 143] . This pathway is depicted in Figure 5 . Both connexin and nucleoside transporters are also present in the organellar membranes and can perform similar functions for the type-II CD38 that is intracellular (reviewed in [138, 139] ). Indeed, it is well documented that CD38 is, by no means, a purely surface protein, but is expressed also in organelles [144] [145] [146] , including the nucleus [147] [148] [149] .
Another alternative solution to this topological conundrum is the possible co-existence of two forms of CD38, type-II and III in cells, as depicted in Figure 5 . This possibility is novel but may offer a more straightforward resolution to the conundrum. It is generally believed that the polarity of membrane proteins is determined predominantly by Figure 5 Schematic of the cADPR/NAADP/CD38-signaling pathway. The target of cADPR is the ryanodine receptor (RyR), a Ca 2+ release channel in the sarco/endoplasmic reticulum (ER), while that of NAADP is the two-pore channel (TPC) in the endolysosomes. Both cADPR and NAADP are synthesized by the membrane enzyme, CD38, which cyclizes NAD in a head-to-tail fashion to produce cADPR and can also catalyze a base-exchange reaction, exchanging the nicotinamide group in NADP with nicotinic acid (NA) to produce NAADP. In some cells, particularly lymphocytes, CD38 is expressed as a type-II membrane protein with the catalytic domain facing outside. The substrate NAD needs to exit the cell via connexin hemi-channels (CNX) to access CD38 and the product, cADPR, is transported back into the cell via nucleoside transporters (NuT) in the plasma membrane to exercise its Ca 2+ signaling function. An alternative scheme also depicted is the existence of the putative type III-CD38 with its catalytic domain facing the cytosol. In this scheme, the substrates in the cytosol have direct access to CD38 and the catalytic domain is also amenable to regulation from the cytosol, such as by protein phosphorylation.
charged residues flanking the hydrophobic core of the trans-membrane segment (reviewed in [150] ). The side with the most net positive charge is generally cytosolic, the "positive inside rule". For CD38, there are four positive charges on each side of the trans-membrane segment, suggesting the possibility that both polarities can be expressed. Indeed, studies using a protease digestion technique [147] and immuno-gold electron-microscopy [148] , have provided evidence that the nuclear CD38 may, in fact, be expressed as a type-III membrane protein.
That a membrane protein can adopt two opposite orientations has precedence. The bacterial multidrug transporter, EmrR, is a protein with four transmembrane helixes. As a functional transporter, it is a homo-dimer. The two identical monomers, however, are in opposite orientation, with the N-terminus of one monomer faces the cytoplasm, while the other faces outside [151] . Another example is the prion protein, a type-II protein similar to CD38, which not only can be synthesized in two opposite trans-membrane orientations, but also in a glycosyl-phosphatidylinositol-linked form. Trans-acting protein factors have been described that can direct prion proteins toward different topologic fates [152] [153] [154] [155] .
One other important consideration for the putative type-III CD38 is the disulfides. CD38 has twelve cysteines in the catalytic domain that are all paired as disulfides [116] . It is a common belief that disulfides are formed only inside the ER, and not in the reductive environment of the cytosol. It is unclear that the type-III CD38, with its catalytic domain facing the cytosol, can form the disulfides. It should be noted that, although rare, a wide range of cytosolic proteins, including those involved in chaperone function, signal transduction, cell growth, etc., have been found to contain inter-as well as intra-molecular disulfide bonds in both mammalian cells and bacteria [156] [157] [158] .
The critical question of disulfide in CD38 has recently been directly addressed. A novel form of CD38 was engineered that expressed efficiently in the cytosol [159] . It was shown that it not only forms intact disulfides but is also fully active in elevating the cytosolic cADPR levels. This engineered cytosolic form of CD38 is thus a novel example challenging the general belief that cytosolic proteins do not possess disulfides and suggests that the information for disulfide formation may be encoded in the primary sequence of CD38. CD38 thus appears to be a novel membrane protein specifically designed to function in both the reductive cytosol as well as the oxidative external environment.
Conclusion
NAD(P) was discovered in 1906 [160] and subsequent work by Warburg and others in the 1930s, established that its primary function is serving as co-enzyme(s) for the redox reactions in cells [161] . Half a century had since passed before the emergence of evidence indicating that NAD(P) also has important Ca 2+ signaling functions, through serving as substrates for cADPR and NAADP. This unexpected discovery had been greeted with healthy doses of skepticism and trivialization. The field has, however, persevered and advanced. Thousands of articles on the subject have been published and the topics of cyclic ADP-ribose or NAADP, have received progressive increase in citation from 1989 to 2010, totaling over 76000 times. In the past two decades, we have seen the identification of the targets of cADPR and NAADP, the elucidation of the enzymatic mechanism of their synthesis to atomic resolution, the documentation of the physiological importance of the signaling pathway through CD38 gene ablation, and the emerging of lysosome-related acidic organelles as fully functional, regulated and relevant, Ca 2+ stores. The progress of the field has brought forth many unanticipated findings and, in some cases, they often challenge the conventional wisdom and dogma. In the immediate future, the regulation of CD38 and the ADP-ribosyl Cyclase represents a new frontier that is likely to usher in new results in membrane protein topology and its relationship with signaling function. 
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